We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Statins Help Lower Risk of Atherosclerosis by Reducing the Size of Arterial Plaques

By LabMedica International staff writers
Posted on 26 Dec 2011
Statins, a class of drugs that help reduce risk of atherosclerosis by lowering levels of low-density lipoproteins (LDL), also decrease the size of arterial plaques by stimulating macrophage emigration.

Investigators at New York University (NY, USA) worked with a novel mouse-transplant model of atherosclerosis regression in which aortic segments from diseased donors were placed into recipients with normal cholesterol levels. More...
With this model they had previously shown that the induction of a chemokine receptor CCR7(C-C chemokine receptor type 7)-dependent emigration process triggered the rapid loss of CD68+ cells (mainly macrophages) from arterial plaques.

In the current study, the investigators examined the effect of statins on macrophage emigration from plaques. They reported in the December 6, 2011, online edition the journal PLoS One that when mice that had been genetically engineered to lack the gene for apolipoprotein E were fed a western diet-fed while being treated with either atorvastatin or rosuvastatin they experienced a substantial reduction in the CD68+ cell content in the plaques despite continued hyperlipidemia. There was a significant increase in CCR7 mRNA in CD68+ cells from both atorvastatin and rosuvastatin treated mice associated with emigration of CD68+ cells from plaques. Mice that lacked both the gene for apolipoprotein E and the gene for CCR7 failed to display a reduction in CD68+ cell content upon statin treatment.

The results of this study indicate that statins, in addition to their traditionally considered effects on atherosclerosis by retarding plaque progression through lowering LDL-cholesterol, may also have additional clinical benefits by accelerating plaque regression through enhancing CCR7 expression and emigration of CD68+ macrophages. These beneficial effects would have been missed if changes in plaque size had been the sole criterion of success.

“Our experimental findings indicate that statins, in addition to lowering LDL cholesterol, have clinical benefits of accelerating plaque regression by a newly discovered mechanism,”said senior author Dr, Michael Garabedian, professor of microbiology and urology at New York University. “It is possible that these drugs could possibly be more beneficial to a wider population of patients potentially reducing the overall lifetime burden of plaque and the prevention of atherosclerosis.”

Related Links:

New York University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.